The ideal candidates for GLP-1 therapy during menopause are those with obesity, insulin resistance, or persistent weight gain despite healthy habits
Your healthcare provider may also consider slowing or pausing dose escalation if gastrointestinal symptoms are severe
Mol Genet Metab 100(Suppl 1):S3S12 Takanashi J, Barkovich AJ, Cheng SF, Weisiger K, Zlatunich CO, Mudge C, Rosenthal P, Tuchman M, Packman S (2003) Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders
She is a member of the American Academy of Family Physicians (AAFP) and the Florida Academy of Family Physicians (FAFP)
Current approaches to treating obesity include lifestyle modifications, pharmacological therapies, and endoscopic or surgical interventions [4]
[10] noticed doubling the risk of cholecystectomy among patients treated with GLP-1RAs